21 CFR Part 111 for Canadian NHP Exporters: A Compliance Guide

Many Canadian natural health product (NHP) companies assume that a Health Canada product licence and a site licence are enough to sell the same product in the United States. They are not. The United States does not recognise the Natural Health Products Regulations. It treats the same bottle as a dietary supplement, governed by a different law and a different set of manufacturing rules known as 21 CFR Part 111.

For a Canadian brand, that gap is where deals stall, shipments get detained and warning letters begin. This guide explains what Part 111 requires, why your Canadian approvals do not carry across the border, and the practical steps to get an NHP export-ready for the US market with confidence.

Executive summary

Canada and the United States run two separate systems for what Canadians call natural health products. In Canada, these products carry an NPN or DIN-HM and are made under Good Manufacturing Practices set out in GUI-0158. In the United States, the identical product is a dietary supplement under the Dietary Supplement Health and Education Act of 1994 (DSHEA), and it must be manufactured in line with 21 CFR Part 111. Neither approval substitutes for the other. A Canadian exporter that wants US shelf space needs to build Part 111 compliance on top of its Canadian file, register the manufacturing site with FDA, appoint a US Agent, verify ingredient identity by testing, handle any new dietary ingredient notification, and support the US importer's own verification duties. The rest of this article works through each of these obligations and the mistakes that most often trip up first-time exporters.

What is 21 CFR Part 111?

What it is. 21 CFR Part 111 is the US Food and Drug Administration's current Good Manufacturing Practice (cGMP) rule for manufacturing, packaging, labelling or holding dietary supplements. It was finalised on 25 June 2007 and applies to any facility that performs those activities for a supplement sold in the United States, including facilities located in Canada.

Why it matters. Part 111 is the standard FDA inspectors measure you against. A supplement made outside these controls is considered adulterated under US law, which exposes it to import detention, refusal, recall and warning letters. For a Canadian brand, non-compliance is not a paperwork problem, it is a market-access problem.

What to do. Treat Part 111 as a separate quality system project, not a translation of your Canadian file. Map your existing GUI-0158 quality management system against Part 111 subparts, close the gaps, and document everything in the master manufacturing record that Part 111 requires for each product and batch size.

Why your Health Canada NPN and site licence do not carry over

What it is. A Health Canada product licence (NPN) authorises sale in Canada and confirms that the product's safety, efficacy and quality were assessed under the Natural Health Products Regulations. A Canadian site licence confirms the site meets GUI-0158 GMP. These are Canadian authorisations with Canadian legal force only.

Why it matters. The United States does not have an NHP category. Under DSHEA, your product is a food, specifically a dietary supplement, and it is not pre-approved by FDA at all. There is no US equivalent of an NPN to apply for. Instead, the burden sits on the manufacturer and distributor to make sure the product is safe, properly made under Part 111 and correctly labelled before it goes to market. In other words, the US system swaps pre-market approval for continuous manufacturer responsibility.

What to do. Do not market or label a US-bound product with Canadian claims, the NPN, or Canadian risk statements. Rebuild the label to US rules, confirm your manufacturing meets Part 111, and keep the two regulatory files clearly separate. If you are still deciding which Canadian licence pathway fits your product in the first place, our guide comparing an NHP licence and a cannabis licence sets out how Health Canada classifies borderline products.

The table below summarises the core differences a Canadian exporter needs to plan around.

Feature	Canada (NHP Regulations)	United States (DSHEA and 21 CFR Part 111)
Product category	Natural health product	Dietary supplement (a category of food)
Pre-market approval	Yes, product licence (NPN) required before sale	No pre-market approval of the product itself
GMP standard	GUI-0158 (NHP GMP)	21 CFR Part 111
Site authorisation	Site licence issued by Health Canada	Facility registration with FDA plus a US Agent
New ingredient route	Product licence application assessment	New Dietary Ingredient (NDI) notification, 75 days before marketing
Health claims	Approved claims tied to the NPN	Structure/function claims with mandatory DSHEA disclaimer

FDA facility registration and the US Agent requirement

What it is. Under the Food Safety Modernization Act, any facility that manufactures, processes, packs or holds food, including dietary supplements, for the US market must register with FDA. A facility outside the United States must also designate a US Agent, a person or business physically in the United States who serves as FDA's point of contact.

Why it matters. Without an active registration and a US Agent, your facility cannot lawfully ship supplements into the United States, and FDA will not process import lines tied to it. Registration is also how FDA finds you for inspection. The trade agreement between Canada, the US and Mexico does not waive this requirement.

What to do. Register the manufacturing facility, appoint a reliable US Agent, and keep the registration current. Food facility registrations must be renewed in every even-numbered year, during the window that runs from 1 October to 31 December. Because 2026 is an even year, the renewal window opens on 1 October 2026. Missing it makes the registration expire and can halt shipments.

Specifications and identity testing under 111.70 and 111.75

What it is. Part 111 requires you to set written specifications for identity, purity, strength and composition, and for contamination limits, at the component, in-process, finished-batch, packaging and labelling stages. Section 111.70 tells you which specifications to establish, and section 111.75 tells you how to determine whether they are met.

Why it matters. This is the single most common Part 111 failure in FDA warning letters. Section 111.75(a)(1)(i) requires at least one appropriate test to verify the identity of every component that is a dietary ingredient. For that identity test, you cannot simply rely on a supplier's certificate of analysis. A certificate can be used for other component specifications, but only if you have first qualified the supplier, confirmed the certificate's reliability, and set up periodic re-confirmation. Skipping identity testing is treated as a core cGMP breach.

What to do. Establish scientifically valid identity test methods for each dietary ingredient, and verify finished batches against your product specifications using a sound sampling plan. Build a supplier qualification file for any certificate you intend to rely on for other specifications. If you lack in-house analytical capacity, our quality control and analytical coordination services can help you select methods and qualify testing laboratories.

Stage	Part 111 expectation	Can a supplier CoA be used?
Identity of a dietary ingredient	At least one appropriate identity test (111.75(a)(1)(i))	No. You must test, unless FDA grants a petition
Other component specifications	Test, or rely on a qualified supplier CoA (111.75(a)(2))	Yes, if the supplier is qualified and re-confirmed
Finished batch	Verify identity, purity, strength, composition and contaminant limits	Testing on a statistical subset or every batch
Packaging and labels	Visual identification and review of supplier documents	Visual check plus invoice or certification review

New Dietary Ingredient notifications and claims

What it is. A New Dietary Ingredient (NDI) is a dietary ingredient that was not marketed in the United States in a supplement before 15 October 1994. If your product contains one, you generally must submit an NDI notification to FDA at least 75 days before marketing, setting out the basis for concluding the ingredient is reasonably expected to be safe.

Why it matters. An ingredient that is well accepted in Canada may still be an NDI in the United States. Marketing a supplement that contains an NDI without the required notification renders the product adulterated. Separately, any structure/function claim, for example that an ingredient supports immune health, must carry the DSHEA disclaimer that the statement has not been evaluated by FDA and the product is not intended to diagnose, treat, cure or prevent any disease, and you must notify FDA of the claim within 30 days of first marketing.

What to do. Screen each ingredient against US market history before you export. Where an NDI notification is needed, budget for the safety dossier and the 75-day clock. Review every claim on the US label so it stays within permitted structure/function language and carries the disclaimer.

FSVP: the US importer's parallel obligation

What it is. The Foreign Supplier Verification Program (FSVP) requires the US importer of record to verify that a foreign supplier produces food, including supplements, to a US-equivalent standard. The Canadian Food Inspection Agency summarises FSVP expectations for exporters. For dietary supplements, FSVP requirements are tailored so that they line up with Part 111 controls.

Why it matters. Even though FSVP sits with the importer, a Canadian exporter that cannot supply the records an importer needs will lose the account. Importers routinely ask for your Part 111 quality documentation, specifications, test results and corrective action history. If you cannot produce them, you are hard to buy from.

What to do. Prepare a supplier information pack that gives importers what FSVP asks for, and keep it current. Our article on FDA supplier oversight and contract manufacturer accountability explains what US buyers expect from their foreign partners.

Part 111 export-readiness checklist

Use this checklist to test whether a Canadian NHP is genuinely ready for the US market.

Manufacturing facility registered with FDA, with renewal scheduled for the 2026 even-year window.
US Agent appointed, with a written agreement and clear responsibilities.
Written specifications set for components, in-process points, finished batches, packaging and labels.
Identity of every dietary ingredient verified by an appropriate, scientifically valid test.
Supplier qualification file in place for any certificate of analysis relied on for other specifications.
Master manufacturing record and batch production records maintained for each product and batch size.
Each ingredient screened for NDI status, with notifications filed where required.
US label rebuilt with a Supplement Facts panel, permitted claims and the DSHEA disclaimer.
Supplier information pack ready to support the importer's FSVP obligations.

Common mistakes Canadian exporters make

Assuming the NPN and Canadian site licence satisfy FDA. They do not, and the US has no product to approve in the first place.
Relying on a supplier certificate of analysis for dietary ingredient identity. Section 111.75 requires you to test.
Letting the FDA registration lapse by missing the even-year renewal window.
Shipping an ingredient that is an NDI in the United States without filing the 75-day notification.
Carrying Canadian claims or the NPN onto the US label instead of using compliant structure/function language with the disclaimer.
Leaving the importer to satisfy FSVP alone, then losing the account when records cannot be produced.

Frequently asked questions

Does my Health Canada site licence count toward FDA compliance?

No. A Health Canada site licence confirms compliance with GUI-0158, the Canadian NHP GMP. FDA assesses your facility against 21 CFR Part 111. The two standards overlap in principle but are audited separately, so you need to demonstrate Part 111 compliance on its own terms, including FDA facility registration and a US Agent.

Do I need to test every dietary ingredient for identity?

Yes. Section 111.75(a)(1)(i) requires at least one appropriate test to verify the identity of each component that is a dietary ingredient, unless FDA grants a petition for alternative testing. A supplier certificate of analysis is not enough for the identity of a dietary ingredient, although it can support other component specifications if the supplier is properly qualified.

What is a US Agent and do I have to have one?

A US Agent is a person or company located in the United States who acts as FDA's contact for your foreign facility. A facility outside the United States must designate a US Agent before it can complete FDA registration. The agent handles communications and can receive information on your behalf, so choose one that is responsive and understands your product.

When is the next FDA registration renewal?

Food facility registrations, including those for dietary supplement facilities, must be renewed in every even-numbered year between 1 October and 31 December. The next window falls in 2026. Diarise it early, because a lapsed registration can stop your US shipments.

Can I use my Canadian label in the United States?

No. US supplements need a Supplement Facts panel, US-format ingredient and allergen information, and any structure/function claim must carry the DSHEA disclaimer. The NPN and Canadian claim wording should not appear on the US label. Plan a separate US label from the start.

Who is responsible for FSVP, me or my US buyer?

The US importer of record holds the FSVP obligation. In practice, though, they rely on you for the documentation that verification depends on, such as your specifications, test results and corrective action records. Being ready to supply that pack makes you an easier supplier to keep.

How MFLRC can help

MF License & Regulatory Consultants helps Canadian NHP companies cross into the US supplement market without surprises. We run a Part 111 gap assessment against your existing GUI-0158 system, write or upgrade the SOPs and master manufacturing records Part 111 expects, and set up identity testing and supplier qualification that hold up under FDA scrutiny. Our regulatory affairs, licensing and import/export team manages FDA facility registration, US Agent coordination and NDI screening, while our audit services prepare you for inspection and for the questions US importers will ask under FSVP.

Whether you are shipping your first pallet south or cleaning up after a detention, we can map the pathway and do the technical work with you.

Book a US market-entry consultation

Conclusion

The distance between a Canadian NHP and a US supplement is not a translation, it is a second compliance system. Part 111 sets the manufacturing bar, FDA registration and a US Agent get you through the door, identity testing keeps you there, and FSVP keeps your importer comfortable. Build these deliberately and the US market becomes a durable growth channel rather than a detention risk. If you would like a second set of expert eyes on your export plan, get in touch with our team.